SCHEMBL2856689

SCHEMBL2856689

COc1ccc(O)c(NC(C)=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
HTT P42858 2/20 0.55
TSHR P16473 1/20 0.55
KDM4E B2RXH2 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
POLB P06746 2/20 0.54
HDAC1 Q13547 2/20 0.54
APOBEC3A P31941 1/20 0.54
GFER P55789 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
PHPT1 Q9NRX4 1/20 0.54
MTNR1A P48039 2/20 0.54
MTNR1B P49286 2/20 0.54
HSD17B1 P14061 1/20 0.54
HSD17B2 P37059 1/20 0.54
ALDH1A1 P00352 3/20 0.52
MAPK1 P28482 2/20 0.51
CYP3A4 P08684 1/20 0.51
HPGD P15428 1/20 0.51
MAPT P10636 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13608498 0.87 POLB (0.56) LMNAHTTTSHRKDM4ESMN1; SMN2
SCHEMBL30567224 0.86 MAPT (0.62) LMNAHTTTSHRKDM4ESMN1; SMN2
SCHEMBL2855386 0.86 MAPT (0.62) LMNAHTTTSHRKDM4ESMN1; SMN2
SCHEMBL7256606 0.86 KMT2A (0.50) KDM4ESMN1; SMN2POLBHDAC1MTNR1A
SCHEMBL27451728 0.84 KDM4E (0.54) LMNAKDM4ESMN1; SMN2POLBHDAC1
SCHEMBL359701 0.82 MAPT (0.56) LMNAHTTTSHRKDM4ESMN1; SMN2
SCHEMBL2502603 0.82 MAPT (0.71) HTTTSHRKDM4ESMN1; SMN2POLB
SCHEMBL1391102 0.82 MEN1 (0.50) HTTSMN1; SMN2HDAC1MTNR1AMTNR1B
SCHEMBL11051072 0.81 POLB (0.50) LMNAHTTTSHRKDM4ESMN1; SMN2
SCHEMBL2847925 0.81 ALDH1A1 (0.64) LMNAHTTTSHRKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0070016-A1 Method and composition for increasing reproduction in mammalian and avian species THE UNIVERSITY OF UTAH (US) 1983-01-19 EP claimed
US-7794761-B2 Methods for inducing anti-anxiety and calming effects in animals and humans SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) 2010-09-14 US disclosed
US-7794761-B2 Methods for inducing anti-anxiety and calming effects in animals and humans SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) 2010-09-14 US disclosed
US-7521468-B2 Compounds for use in weight loss and appetite suppression in humans SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) 2009-04-21 US disclosed
US-7521468-B2 Compounds for use in weight loss and appetite suppression in humans SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) 2009-04-21 US disclosed
EP-1765338-A1 METHODS FOR INDUCING ANTI-ANXIETY AND CALMING EFFECTS IN ANIMALS AND HUMANS Seroctin Research & Technologies, Inc. (US) 2007-03-28 EP disclosed
US-20060223796-A1 Novel compounds for use in weight loss and appetite suppression in humans SAVANNA HEALTH LLC 2006-10-05 US disclosed
WO-2006017281-A1 METHODS FOR INDUCING ANTI-ANXIETY AND CALMING EFFECTS IN ANIMALS AND HUMANS SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) 2006-02-16 WO disclosed
US-20050250772-A1 Methods for inducing anti-anxiety and calming effects in animals and humans SAVANNA HEALTH LLC 2005-11-10 US disclosed
US-20040209877-A1 Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans SEROCTIN RESEARCH & TECHNOLOGY, INC. 2004-10-21 US disclosed
EP-0343574-B1 4(1H)-quinolone derivatives KIRIN BREWERY (JP) 1994-07-27 EP disclosed
US-5081121-A Cardiotonic agents KIRIN BEER KABUSHIKI KAISHA (JP) 1992-01-14 US disclosed
EP-0343574-A1 4(1H)-quinolone derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 1989-11-29 EP disclosed
EP-0070016-A1 Method and composition for increasing reproduction in mammalian and avian species THE UNIVERSITY OF UTAH (US) 1983-01-19 EP disclosed
EP-0006220-B1 PROCESS FOR THE PREPARATION OF 3-ACYL-2-ALKYL(ARYL)-1.3.2-BENZOXAZAPHOSPHOLANES HOECHST AKTIENGESELLSCHAFT (DE) 1981-08-19 EP disclosed
EP-0006195-B1 PROCESS FOR PREPARING DELTA-3 1-OXOPHOSPHOLENES HOECHST AKTIENGESELLSCHAFT (DE) 1981-05-13 EP disclosed
US-4263231-A REACTING DICHLOROPHOSPHANES AND 2-N-ACYLAMINOPHENOLS HOECHST AKTIENGESELLSCHAFT (DE) 1981-04-21 US disclosed
US-4247488-A Process for the preparation of 1-oxophosphol-Δ3 -enes HOECHST AKTIENGESELLSCHAFT (DE) 1981-01-27 US disclosed
EP-0006220-A1 Process for the preparation of 3-Acyl-2-alkyl(aryl)-1.3.2-benzoxazaphospholanes HOECHST AKTIENGESELLSCHAFT (DE) 1980-01-09 EP disclosed
EP-0006195-A1 Process for preparing delta-3 1-oxophospholenes HOECHST AKTIENGESELLSCHAFT (DE) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209877-A1 Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans HAAO, HMOX1, IDO1 LMNA 1850/4885HTT 1548/4885TSHR 3911/4885
US-20050250772-A1 Methods for inducing anti-anxiety and calming effects in animals and humans CALM1, HAAO, MYB LMNA 820/4885HTT 1003/4885TSHR 4265/4885
US-20060223796-A1 Novel compounds for use in weight loss and appetite suppression in humans CPT1B, EGLN3, MYB LMNA 2189/4885HTT 1076/4885TSHR 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.